PCSK9 inhibitors for COVID‐19: an opportunity to enhance the antiviral action of interferon in patients with hypercholesterolaemia

Familial hypercholesterolaemia and COVID‐19: triggering of increased sustained cardiovascular risk

(2020) Alpo Vuorio et al.   JOURNAL OF INTERNAL MEDICINE

May statins and PCSK9 inhibitors be protective from COVID-19 in familial hypercholesterolemia subjects?

(2020) Roberto Scicali et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

Meta-analysis of Effectiveness of Statins in Patients with Severe COVID-19

(2020) Chia Siang Kow et al.   AMERICAN JOURNAL OF CARDIOLOGY

Prevention of endothelial dysfunction and thrombotic events in COVID-19 patients with familial hypercholesterolemia

(2020) Alpo Vuorio et al.   Journal of Clinical Lipidology

Dengue virus induces PCSK9 expression to alter antiviral responses and disease outcomes

(2020) Esther Shuyi Gan et al.   JOURNAL OF CLINICAL INVESTIGATION

Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities

(2019) A. Vuorio et al.   JOURNAL OF INTERNAL MEDICINE

Proprotein convertase subtilisin/kexin type 9 inhibits interferon β expression through interacting with ATF-2

(2018) Zhubing Li et al.   FEBS LETTERS

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)

(2013) Maryssa Canuel et al.   PLoS One

Increased Expression of LDL Receptor-Related Protein 1 during Human Cytomegalovirus Infection Reduces Virion Cholesterol and Infectivity

(2012) Nicole Gudleski-O'Regan et al.   Cell Host & Microbe